Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M...
Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following...
Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained...
Peer-reviewed publication in “The Oncologist” is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event...
Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”)...
Advanced Integration Efforts to Consolidate Subsidiaries and Pulled Forward Two Quarters of Rolvedon Demand Promotes Paul Schwichtenberg to President...
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Assertio...